Physician profile
Stephen Tate
NPI 1780736975
$2,447.33
in general payments reported to CMS, 2019-2025
19 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $308 · 2021: $42.07 · 2022: $111 · 2023: $149 · 2024: $198 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.43 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $1,250.00 | 2019 | |
| Abbvie INC. | $234.14 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Regeneron Healthcare Solutions, INC. | $160.11 | 2019-2025 | Eylea, Eylea Hd |
| Glaukos Corporation | $131.99 | 2020 | |
| Harrow Eye, LLC | $121.59 | 2025 | Vevye |
| Allergan, INC. | $112.98 | 2019-2020 | |
| Glaxosmithkline, LLC. | $81.40 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.97 | 2019-2020 | |
| Rxsight INC | $70.45 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $39.71 | 2019 | |
| Genentech USA, INC. | $33.59 | 2025 | Vabysmo |
| Dompe US, INC. | $22.63 | 2024 | Oxervate |
| Biotissue Holdings INC. | $22.32 | 2023 | |
| Amgen INC. | $21.08 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $15.80 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $15.38 | 2025 | Lotemax, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $14.96 | 2019 | |
| Eyepoint US, INC. | $14.27 | 2020 | |
| Ocular Therapeutix, INC. | $12.96 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.